// App-Quantinova.ai

: Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study

Researchers

Presenter

  • Hang Quach

Principal Investigators

  • Sung-Soo Yoon

  • Kihyun Kim

  • Ji Hyun Lee

  • Chandramouli Nagarajan

  • Phoebe Joy Ho

  • Michael S.Y. Low

  • Wei-Han Huang

  • Raymond Wong

  • Nina Liao

  • ChingFeng Lin

  • Matthew Britland

  • Julia Li

  • Stella Chai

  • Jin Seok Kim

Medical Centers

  • Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan Univ. Sch. of Med. Samsung Medical Center, Seoul, Korea, Republic of (South)

  • Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong

  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)

  • University of Melbourne, St. Vincent's Hospital, Melbourne, Australia

  • Royal Prince Alfred Hospital and University of Sydney, Camperdown, Sydney, Australia

  • Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Monash Medical Centre, Melbourne, Australia

  • Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea

  • Parexel International, Taipei, Taiwan

  • SingHealth Duke-NUS Blood Cancer Center and Singapore General Hospital, Singapore, Singapore

  • Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City, Taiwan

Locations

  • Hong Kong

  • Republic of South Korea

  • Australia

  • Singapore

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • carfilzomib Intravenous

Outcome

  • N/A


Study Design

  • Single Arm

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A